These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 30415407)

  • 1. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
    Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
    Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
    Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N
    J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
    Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
    Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
    J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
    Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
    Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 18. Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.
    Wang D; Zhou D; Liu X; Xu Z; Bai T; Hou X
    Trials; 2023 Dec; 24(1):778. PubMed ID: 38041136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
    Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
    Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial.
    Boltin D; Zvidi I; Raskin M; Kayless H; Schmilovitz-Weiss H; Gingold-Belfer R; Niv Y; Dickman R
    Dig Dis; 2018; 36(4):257-263. PubMed ID: 29791895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.